JP2021175391A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021175391A5 JP2021175391A5 JP2021056390A JP2021056390A JP2021175391A5 JP 2021175391 A5 JP2021175391 A5 JP 2021175391A5 JP 2021056390 A JP2021056390 A JP 2021056390A JP 2021056390 A JP2021056390 A JP 2021056390A JP 2021175391 A5 JP2021175391 A5 JP 2021175391A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cdr
- amino acid
- acid sequence
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 112
- 125000003275 alpha amino acid group Chemical group 0.000 claims 57
- 239000000427 antigen Substances 0.000 claims 32
- 102000036639 antigens Human genes 0.000 claims 32
- 108091007433 antigens Proteins 0.000 claims 32
- 229920001184 polypeptide Polymers 0.000 claims 31
- 108090000765 processed proteins & peptides Proteins 0.000 claims 31
- 102000004196 processed proteins & peptides Human genes 0.000 claims 31
- 102000040430 polynucleotide Human genes 0.000 claims 6
- 108091033319 polynucleotide Proteins 0.000 claims 6
- 239000002157 polynucleotide Substances 0.000 claims 6
- 241000024188 Andala Species 0.000 claims 4
- 102000010956 Glypican Human genes 0.000 claims 4
- 108050001154 Glypican Proteins 0.000 claims 4
- 108050007237 Glypican-3 Proteins 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 235000001014 amino acid Nutrition 0.000 claims 3
- 150000001413 amino acids Chemical group 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- 102000009490 IgG Receptors Human genes 0.000 claims 1
- 108010073807 IgG Receptors Proteins 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020062357 | 2020-03-31 | ||
| JP2020062357 | 2020-03-31 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021175391A JP2021175391A (ja) | 2021-11-04 |
| JP2021175391A5 true JP2021175391A5 (enExample) | 2024-04-03 |
Family
ID=77928944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021056390A Pending JP2021175391A (ja) | 2020-03-31 | 2021-03-30 | 免疫活性化多重特異性抗原結合分子およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230147840A1 (enExample) |
| EP (1) | EP4126958A4 (enExample) |
| JP (1) | JP2021175391A (enExample) |
| KR (1) | KR20220161156A (enExample) |
| CN (1) | CN115315447A (enExample) |
| AR (1) | AR121692A1 (enExample) |
| SG (1) | SG11202105566TA (enExample) |
| TW (1) | TW202204410A (enExample) |
| WO (1) | WO2021200896A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2647707T (lt) * | 2010-11-30 | 2018-11-12 | Chugai Seiyaku Kabushiki Kaisha | Citotoksiškumą indukuojantis terapinis agentas |
| MX389442B (es) | 2013-11-11 | 2025-03-20 | Chugai Pharmaceutical Co Ltd | Región variable de anticuerpo modificada que contiene molécula de unión al antígeno. |
| WO2016076345A1 (ja) | 2014-11-11 | 2016-05-19 | 中外製薬株式会社 | 改変された抗体可変領域を含む抗原結合分子のライブラリ |
| TW201938194A (zh) | 2017-12-05 | 2019-10-01 | 日商中外製藥股份有限公司 | 包含結合cd3及cd137的改變的抗體可變區之抗原結合分子 |
| WO2019232523A1 (en) * | 2018-06-01 | 2019-12-05 | The Board Of Trustees Of The Leland Stanford Junior University | Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof |
| WO2023036043A1 (zh) * | 2021-09-09 | 2023-03-16 | 广东东阳光药业有限公司 | 抗癌结合分子及其应用 |
| EP4413043A4 (en) * | 2021-10-07 | 2025-11-12 | Nat Res Council Canada | Single-domain anti-BCMA antibodies and therapeutic constructs |
| CA3234068A1 (en) * | 2021-10-07 | 2023-04-13 | National Research Council Of Canada | Anti-cd3 monoclonal antibodies and therapeutic constructs |
| WO2025109518A1 (en) * | 2023-11-21 | 2025-05-30 | Janssen Biotech, Inc. | Methods for treatment of myeloproliferative neoplasms |
| WO2025210181A1 (en) * | 2024-04-04 | 2025-10-09 | Cdr-Life Ag | Antigen binding proteins targeting an hla-restricted kk-lc-1 peptide |
| WO2025226541A2 (en) * | 2024-04-26 | 2025-10-30 | Janssen Biotech, Inc. | Klk2xcd3 antibody and an anti-cancer agent for treating prostate cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2647707T (lt) | 2010-11-30 | 2018-11-12 | Chugai Seiyaku Kabushiki Kaisha | Citotoksiškumą indukuojantis terapinis agentas |
| EP2948475A2 (en) | 2013-01-23 | 2015-12-02 | AbbVie Inc. | Methods and compositions for modulating an immune response |
| MX380176B (es) | 2014-04-07 | 2025-03-12 | Chugai Pharmaceutical Co Ltd | Molecula ligada a antigeno inmunoactivada. |
| MA40764A (fr) * | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| TW201938194A (zh) * | 2017-12-05 | 2019-10-01 | 日商中外製藥股份有限公司 | 包含結合cd3及cd137的改變的抗體可變區之抗原結合分子 |
| SG11202102882YA (en) * | 2018-09-28 | 2021-04-29 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule comprising altered antibody variable region |
| SG11202101912UA (en) * | 2018-09-28 | 2021-04-29 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecules capable of binding cd3 and cd137 but not simultaneously |
-
2021
- 2021-03-30 US US17/914,855 patent/US20230147840A1/en active Pending
- 2021-03-30 CN CN202180020903.4A patent/CN115315447A/zh not_active Withdrawn
- 2021-03-30 AR ARP210100788A patent/AR121692A1/es unknown
- 2021-03-30 JP JP2021056390A patent/JP2021175391A/ja active Pending
- 2021-03-30 KR KR1020217031417A patent/KR20220161156A/ko not_active Withdrawn
- 2021-03-30 SG SG11202105566TA patent/SG11202105566TA/en unknown
- 2021-03-30 WO PCT/JP2021/013456 patent/WO2021200896A1/en not_active Ceased
- 2021-03-30 EP EP21780692.6A patent/EP4126958A4/en not_active Withdrawn
- 2021-03-30 TW TW110111557A patent/TW202204410A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021175391A5 (enExample) | ||
| CN115715202B (zh) | 抗体药物缀合物及其制备方法和用途 | |
| TWI585104B (zh) | 基於vl和vhh可變區衍生物的高親和力抗聚集抗體 | |
| JP2022031784A5 (enExample) | ||
| JP7031810B2 (ja) | 抗ｐｄ－１／抗ｈｅｒ２天然抗体構造形態のヘテロダイマー系二重特異性抗体及びその製造方法 | |
| US11987609B2 (en) | Proteinaceous heterodimer and use thereof | |
| JP2022009816A5 (enExample) | ||
| CN118063619A (zh) | 工程化的异源二聚体蛋白质 | |
| JPWO2019234220A5 (enExample) | ||
| CN113195530B (zh) | 抗体融合蛋白、制备方法及其应用 | |
| JP2021513366A (ja) | 抗ｐｄ−１／抗ｈｅｒ２天然抗体構造ヘテロダイマー系の二重特異性抗体及びその製造方法 | |
| AU2021224200A1 (en) | Engineered anti-HER2 bispecific proteins | |
| JP2022051553A5 (enExample) | ||
| TW202222824A (zh) | Egfr結合複合物及其製備和使用方法 | |
| JP2022537823A (ja) | 共有結合型多重特異性抗体 | |
| CN112159473B (zh) | 重组人源化抗人白介素23单克隆抗体的纯化方法 | |
| WO2020192648A1 (en) | Proteinaceous heterodimer and use thereof | |
| CN108290942A (zh) | 与人及小鼠信号素3a交联的抗体及其用途 | |
| CN120659804A (zh) | 多价蛋白质及筛选方法 | |
| WO2024131949A1 (zh) | Anti-cMet抗体、抗体药物偶联物及其制备方法和用途 | |
| EP4169940A1 (en) | Immunogenicity-reduced low-molecular antibody and method for producing same | |
| CN111558038B (zh) | 一种用于癌症治疗的免疫检查点抑制剂 | |
| CN115433277A (zh) | 抗cd38兔重组单克隆抗体的制备及应用 | |
| CN117264065B (zh) | 一种her2抗原结合分子及其应用 | |
| WO2024077777A1 (zh) | 多功能重组抗体及其制备方法和应用 |